Impact of Molecular Drug Susceptibility Testing on the Time to Multidrug-resistant Tuberculosis Treatment Initiation
- PMID: 32893517
- PMCID: PMC7476798
- DOI: 10.3346/jkms.2020.35.e284
Impact of Molecular Drug Susceptibility Testing on the Time to Multidrug-resistant Tuberculosis Treatment Initiation
Abstract
Background: The purpose of this study was to evaluate the current status and trends in the coverage of molecular drug susceptibility testing (mDST), and the impact of mDST on the time to multidrug-resistant tuberculosis (MDR-TB) treatment initiation in Korea.
Methods: We included confirmed rifampin-resistant (RR)/MDR-TB patients who submitted application forms for novel drug uses to the National TB Expert Review Committee from September 1, 2016 to November 30, 2019. We retrospectively reviewed their medical records.
Results: Of the 621 MDR/RR-TB patients, mDST was performed in 442 (71.2%); Xpert MTB/RIF (Xpert) alone in 109 (17.6%), MTBDRplus line probe assay (LPA) alone in 199 (32.0%), and both Xpert and LPA in 134 (21.6%) patients. The coverage rate of mDST has gradually increased to 70% in 2015, 50.7% in 2016, 67.9% in 2017, 75.2% in 2018, and 79.4% in 2019 (P for trend < 0.001). Median time to MDR-TB treatment initiation was 35 days (interquartile range25-75 0-72), which has gradually decreased during the study period (P < 0.001). Independent predictors of shorter time to MDR-TB treatment initiation were retreatment case (adjusted hazard ratio [aHR], 1.30; 95% confidence interval [CI], 1.10-1.54), Xpert testing (aHR, 2.42; 95% CI, 2.03-2.88), and LPA testing (aHR, 1.83; 95% CI, 1.55-2.16). Transfer to another healthcare facility was inversely related to shorter time to treatment initiation (aHR, 0.74; 95% CI, 0.63-0.88).
Conclusion: mDST coverage is gradually increasing and contributes to reducing the time to MDR-TB treatment initiation. Further efforts are needed to achieve universal access to mDST and to properly integrate mDST into routine clinical practice.
Keywords: Drug Resistance; Korea; Multidrug-Resistant Tuberculosis; Time to Treatment; Tuberculosis.
© 2020 The Korean Academy of Medical Sciences.
Conflict of interest statement
The authors have no potential conflicts of interest to disclose.
Figures
References
-
- Cirillo DM, Miotto P, Tortoli E. Evolution of phenotypic and molecular drug susceptibility testing. Adv Exp Med Biol. 2017;1019:221–246. - PubMed
-
- World Health Organization. Policy statement. WHO policy statement: molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis. [Updated 2008]. [Accessed May 30, 2020]. https://www.who.int/tb/features_archive/policy_statement.pdf.
-
- World Health Organization. Policy statement. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. [Updated 2011]. [Accessed May 30, 2020]. https://apps.who.int/iris/bitstream/handle/10665/44586/9789241501545_eng.... - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous